Macrophages, Myeloid, and Dendritic Cells in Tumor Immunity and Immunotherapy

 Monday, May 9, 2022     10:15 AM – 12:15 PM ET     Oregon Ballroom 201

Macrophages, Myeloid, and Dendritic Cells in Tumor Immunity and Immunotherapy

Chairs

• Evan Lind, Oregon Hlth. and Sci. Univ.
• Kenneth Murphy, Washington Univ. in St Louis Sch. of Medicine

Speakers

• Briaunna M.N. Minor, Univ. of Rochester Med. Ctr., Estradiol effects on polymorphonuclear cell production and actions contribute to estrogen-mediated lymphangioleiomyomatosis (LAM) progression
• Stacy K. Thomas, Perelman Sch. of Med., Univ. of Pennsylvania, Liver macrophage subsets differentially regulate metastasis in pancreatic cancer
• Irene Saha, Cincinnati Children’s Hosp. and Med. Ctr., The B cell adapter for PI3K (BCAP) promotes M2 macrophage phenotype and safeguards tumors from immune surveillance
• David J. Friedman, Mayo Clin., Enhanced anti-tumor immunity in ST8Sia6 knockout mice
• Jiaying Zheng, Mayo Clin. Grad. Sch. of BioMed. Sci., Hv1 proton channels control myeloid landscape and promote glioma progression
• Patrick A. Flynn, Oregon Hlth. and Sci. Univ., Impact of constitutive FLT3 signaling on dendritic cell development and function in a genetically-engineered mouse model of Acute Myeloid Leukemia
• Renee Wu, Washington Univ. in St Louis Sch. of Med., Mechanisms of CD40-dependent cDC1 licensing beyond co-stimulation